However, such adverse events have been rare with TGF-βi and may be ameliorated in COVID-19 by concomitant therapies such as steroids and anti-inflammatory agents that are already given in hospitalized patients with severe illness requiring oxygen therapy (84, 103). Here, CACNA1A is linked to COVID-19.